Skip to main content

Find Clinical Trials

Home
Conditions
Prostate Cancer Metastatic

Clinical trial condition

Prostate Cancer Metastatic

Explore clinical trials studying Prostate Cancer Metastatic. Study availability and eligibility vary by location and protocol.

85 public trials 26 recruiting studies

Refine in advanced search Browse all conditions

Prostate Cancer Metastatic trial results

Completed

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

NCT03223727

Conditions: Bone Metastases, Prostate Cancer Metastatic
Locations: The Netherlands Cancer Intitute Amsterdam, Netherlands

Franciscus Gasthuis & Vlietland Rotterdam, Netherlands

View Trial Details

Completed

The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

NCT04179968

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations: UT Southwestern Medical Center Dallas, Texas, United States

View Trial Details

Completed

MSG Use With 18F-DCFPyL PET/CT Imaging

NCT03693742

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +10 more
Locations: BC Cancer Vancouver, British Columbia, Canada

View Trial Details

Completed

Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research

NCT04590976

Conditions: Behavior, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +19 more
Locations: NHS Grampion Aberdeen, United Kingdom

Besti Cadwaladr University Bangor, United Kingdom

Ysbyty Gwynedd Hospital Bangor, United Kingdom

Hamphire Hospitals NHS Foundation Trust Basingstoke, United Kingdom

View all 35 locations

View Trial Details

Completed

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

NCT03434158

Conditions: Prostate Cancer Metastatic
Locations: Complexo Hospitalario Universitario de Santiago Santiago de Compostela, A Coruña, Spain

ICO L'Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario Central de Asturias Oviedo, Principality of Asturias, Spain

Hospital Clínic de Barcelona Barcelona, Spain

View Trial Details

Completed

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

NCT02485691

Conditions: Prostate Cancer Metastatic
Locations: Investigational Site Number 040002 Linz, Austria

Investigational Site Number 040003 Vienna, Austria

Investigational Site Number 040004 Vienna, Austria

Investigational Site Number 056013 Bruges, Belgium

View all 65 locations

View Trial Details

Completed

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

NCT02961257

Conditions: Prostate Cancer Metastatic
Locations: Hôpital Jean Minjoz Besançon, France

Hôpital Saint André, CHU de Bordeaux Bordeaux, France

Clinique Pasteur-CFRO Brest, France

Centre Maurice Tubiana Caen, France

View all 31 locations

View Trial Details

Completed

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

NCT03223597

Conditions: Bone Metastases, Neurologic Manifestations, Pain, +3 more
Locations: Meander Medical Center Amersfoort, Utrecht, Netherlands

Jeroen Bosch Hospital 's-Hertogenbosch, Netherlands

Noordwest Ziekenhuisgroep Alkmaar, Netherlands

Zorggroep Twente Almelo, Netherlands

View all 20 locations

View Trial Details

Completed

Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel

NCT03295565

Conditions: Metastasis, Neoplasm Metastasis, Neoplasms, +4 more
Locations: Noordwest Ziekenhuisgroep Alkmaar, Netherlands

Bovenij ziekenhuis Amsterdam, Netherlands

Rode Kruis Ziekenhuis Beverwijk, Netherlands

Tergooi Ziekenhuizen Blaricum, Netherlands

View all 19 locations

View Trial Details

Completed

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

NCT02815033

Conditions: Prostate Cancer Metastatic
Locations: Leiden University Medical Center Leiden, Netherlands

View Trial Details